Latest news for MiniLuxe Hldg (OTC:MNLXF) Stock

MiniLuxe Holding Corp owns and operates nail and beauty salons and provides consumers with nail, hand, foot care, and waxing services, and sells personal beauty products. The Company operates in only one geographical region which is the United States of America.

MINILUXE HLDGS CORP by MiniLuxe Holding Corp.

MiniLuxe Holding Corp

Small Cap Consumer Research analyst Eric Beder reiterates a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Buy and maintains $25 price target.

News

Price Target

Reiteration

Analyst Ratings

Small Cap Consumer Research Reiterates Buy on a.k.a. Brands Holding, Maintains $25 Price Target

Baird analyst Jeffrey Meuler maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Outperform and raises the price target from $517 to $565.

Baird Maintains Outperform on Gartner, Raises Price Target to $565

Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC ("LSM") has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit <a href="https://www.globenewswire.com/Tracker?data=n4ZXPR5f35s_LdJqmLeA0riv8sYFJUozzKJfdSljI8H8ZCmDNdHfsvPKBKDuYPbpVfeXgJ-speCRj3ct9T27_8TZ0wXECm1JzpAPyrTtNKI=">www.dna4addiction.com</a>. Avalon owns a 40% equity interest in LSM.

Biotech

General

ALBT

Avalon's Laboratory Services MSO Launches DNA Testing Kit For Predisposition To Opioid Addiction

Baird analyst William Power maintains Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>) with a Outperform and lowers the price target from $43 to $35.

INFA

Baird Maintains Outperform on Informatica, Lowers Price Target to $35

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $5 price target.

SGMO

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target

DuPont De Nemours, Inc. (NYSE:&nbsp;DD) shares are trading higher after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com//node/40061638" rel="noreferrer noopener">second-quarter adjusted EPS and sales.</a>
Sales rose 2%&nbsp;Y/Y to&nbsp;$3.171 billion,&nbsp;beating the consensus of&nbsp;$3.049 billion. Organic sales remained flat Y/Y, with a 2% increase in volume offset by a 2% decrease in price.
Organic sales by region YoY: EMEA&nbsp;-7%,&nbsp;U.S./Canada&nbsp;-2%&nbsp;and Asia Pacific&nbsp;+3%.
DuPont's operating EBITDA rose 8%&nbsp;Y/Y to $798 million, and its margin expanded by 130 bps Y/Y to&nbsp;25.2%.
Electronics &amp; Industrial sales totaled&nbsp;$1.508 billion&nbsp;(+15%&nbsp;Y/Y), and the operating EBITDA margin expanded by 120 bps Y/Y to&nbsp;27.8%.
Water &amp; Protection sales were&nbsp;$1.391 billion&nbsp;(-7%&nbsp;Y/Y), and the operating EBITDA margin expanded by 10 bps Y/Y to&nbsp;24.7%.
Adjusted EPS for the quarter was&nbsp;$0.97 (+14% Y/Y),&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$0.85.</a>
Operating cash flow from continuing activities for the quarter was $527 million, compared to $400 million a year ago. Adjusted free cash flow was $425 million (+53% Y/Y). As of June-end, DuPont held cash and equivalents of $1.51 billion.
Lori Koch, DuPont Chief Executive Officer, said, &#8220;Earlier this week we announced the closing of the Donatelle acquisition which expands our healthcare offerings through enhanced expertise in medical device markets closely related to the Spectrum business which we purchased last year.&#8221;
&#8220;In addition, we are advancing our strategic priorities and have made progress in planning key actions and milestones related to our previously announced intent to separate our electronics and water businesses.&#8221;
Q3 Outlook: DuPont expects net sales of ~$3.20 billion versus the consensus of $3.20 billion, and A<a href="https://www.benzinga.com/calendars/guidance">djusted EPS of ~$1.03 against the consensus of $1.01.</a>
Antonella Franzen, DuPont Chief Financial Officer, said, &#8220;For the third quarter of 2024, we expect a return to year-over-year organic sales growth for DuPont led by E&amp;I with sales and earnings growth expected from W&amp;P beginning in the fourth quarter.&#8221;
2024 Outlook: DuPont raised the outlook for adjusted EPS to $3.70 &#8211; $3.80 (from $3.45 – $3.75) versus $3.63 consensus and revenue of $12.40 billion &#8211; $12.50 billion (prior $12.1 billion – $12.4 billion) versus $12.26 billion consensus.
In May, the company&nbsp;announced its plan to split into three distinct publicly traded entities. The separation will include its Electronics and Water businesses, executed <a target="_blank" href="https://www.benzinga.com/news/24/05/38987084/whats-happening-with-chemical-company-duponts-shares-today" rel="noreferrer noopener">in a tax-free manner for shareholders</a>.
After the separation, New DuPont will continue as a premier diversified industrial company, while Electronics and Water will benefit from increased focus in their industries.
The separations, expected to be tax-free for U.S. shareholders, should be completed within 18 to 24 months, subject to customary conditions and regulatory approvals.
Related: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39044983/duponts-strategic-split-could-unlock-value-but-pfas-risks-loom-large-says-bofa-anal" rel="noreferrer noopener">DuPont&#8217;s Strategic Split Could Unlock Value, But PFAS Risks Loom Large, Says BofA Analyst</a>
Price Action: DD&nbsp;shares are up 4.50% at $84.03 premarket at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Earnings

Equities

Large Cap

Guidance

Movers

TINT

Chemical Company DuPont Shines In Q2: Earnings Beat, Boosts Outlook

Baird analyst Peter Arment maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Outperform and raises the price target from $84 to $113.

Baird Maintains Outperform on Howmet Aerospace, Raises Price Target to $113

JBLU

JetBlue Signs Agreement With World Fuel Services To Supply Blended Sustainable Aviation Fuel At JFK Airport Starting Q4 2024; Initial 12-Month Deal Includes Minimum 1M Gallons Of Neat SAF With Option For Up To 4M Additional Gallons; JetBlue Invites New York Businesses To Help Scale SAF Market

Baird analyst David Rodgers maintains Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) with a Neutral and raises the price target from $27 to $30.

Baird Maintains Neutral on Highwoods Props, Raises Price Target to $30

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy and maintains $120 price target.

CMPS

HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target

Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n40064718/boeing-reports-second-quarter-results" rel="noreferrer noopener">second-quarter 2024 results</a> and named Kelly Ortberg its new President and CEO, effective August 8, 2024.
Boeing reported a second-quarter revenue decline of 15% year-over-year to $16.866 billion, missing the consensus of $17.23 billion.
Adjusted loss per share expanded to $(2.90) from $(0.93) in the same quarter of 2024, missing the consensus of $(1.91).
The company stated that the results primarily reflect lower commercial delivery volume and losses on fixed-price defense development programs.
Boeing recorded an adjusted operating loss of $(1.392) billion for the quarter, compared to $(390) million a year ago. The core operating loss margin was (8.3)%.
Commercial Airplanes revenue fell 32% YoY to $6.003 billion, reflecting lower deliveries and planned higher period costs, including research and development.
Deliveries declined by 32%, and 92 airplanes were delivered, and the backlog included over 5,400 airplanes valued at $437 billion.
The 737 program gradually increased production during the quarter and still plans to increase production to 38 per month by year end.
Defense, Space &amp; Security revenue fell 3% year over year to $6.021 billion. The backlog was $59 billion, of which 31% represents orders from customers outside the U.S.
Global Services revenue grew by 3% YoY to $4.889 billion. The operating margin contracted 20 bps to 17.8%, reflecting higher commercial volume and mix.
Operating cash outflow for the six months ended June 30 totaled $(7.285) billion, compared to cash provided of $2.557 billion YoY; free cash outflow was $(4.3) billion.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Boeing Q2 2024 Earnings Call &#x7C; $BA" width="500" height="281" src="https://www.youtube.com/embed/mraW07D-qZw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Debt was $57.9 billion, up from $47.9 billion at the beginning of the quarter due to the issuance of new debt.
At the end of the quarter, cash and investments in marketable securities totaled $12.6 billion, and the total company backlog was $515.874 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39928770/boeing-resumes-737-max-deliveries-to-china-after-regulatory-delay-report" rel="noreferrer noopener">Boeing Resumes 737 MAX Deliveries To China After Regulatory Delay: Report</a>
Additionally, Boeing announced Robert K. &#8220;Kelly&#8221; Ortberg as the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n40064789/boeing-board-names-kelly-ortberg-president-and-ceo" rel="noreferrer noopener">company&#8217;s new president and chief executive officer</a>, effective August 8, 2024. Ortberg will also serve on Boeing&#8217;s Board of Directors.
Ortberg, 64, has over 35 years of aerospace experience. He began at Texas Instruments in 1983, joined Rockwell Collins in 1987, and became CEO in 2013.
He led its integration with United Technologies and RTX until 2021. He serves on the boards of RTX and Aptiv PLC and is a former Chair of the Aerospace Industries Association.
Price Action: BA shares are trading higher by 2.06% at $190.70 premarket at the last check on Wednesday.
Photo via Shutterstock

Management

Tech

Boeing's Q2 Earnings: Huge Revenue Decline, Lower Deliveries, Names Former Aerospace Industries Association Chair Kelly Ortberg As New CEO

Baird analyst Michael Halloran maintains Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) with a Neutral and raises the price target from $16 to $19.

HAYW

Baird Maintains Neutral on Hayward Holdings, Raises Price Target to $19

Macro Economic Events

Econ #s

Economics

USA ADP Nonfarm Employment Change For July 122K Vs 147K Est.; 155K Prior

Baird analyst Ghansham Panjabi maintains Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) with a Outperform and raises the price target from $30 to $36.

Baird Maintains Outperform on Graphic Packaging Holding, Raises Price Target to $36

Macro Notification

ADP Nonfarm Employment Change (Jul) +122K vs +147K Est.

Fibromyalgia is a "diagnosable condition" in people suffering from Long COVID according to NASEM1 &nbsp;
Diagnosing fibromyalgia in Long COVID patients is expected to expand the potential addressable market for Tonmya relative to pre-COVID-19 pandemic estimates2
Tonmya is a potential new first-line non-opioid analgesic under development for the management of fibromyalgia with Fast Track designation: NDA submission target is second half of 2024, with potential for FDA approval in 2025
CHATHAM, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today provided an update on the potential impact on the size of the fibromyalgia market for its development candidate Tonmya (TNX-102 SL or cyclobenzaprine HCl sublingual tablets), based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM) announced on June 11, 20241.

TNXP

Tonix Pharmaceuticals Announces Potential Impact Of The U.S. National Academies New Definition Of Long COVID On The Size Of The Fibromyalgia Market For Tonmya

Baird analyst Michael Halloran maintains Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) with a Neutral and raises the price target from $57 to $60.

Baird Maintains Neutral on Flowserve, Raises Price Target to $60

MNDY

Monday.com Announces Full Release Of Portfolio Management Solution; New Capabilities Enhance Strategic Initiative Management, Streamline Operations, And Boost Productivity Across Teams And Departments

In a recent development, chip ETFs have experienced a significant upswing as a result of President Biden&#8217;s decision to exempt some allies from the new rule governing chip exports to China.
This movement also comes on the heels of&nbsp;Advanced Micro Devices, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) <a href="https://www.benzinga.com/news/earnings/24/07/40060832/amd-skyrockets-over-9-lifting-along-with-ai-rival-nvidia-whats-going-on">posting its second-quarter</a> results which exceeded expectations and guided the current quarter's revenue above consensus. 
What Happened: According to <a href="https://pro.benzinga.com">Benzinga Pro</a>, on Wednesday, the GraniteShares 2x Long NVDA Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDL#NASDAQ">NVDL</a>), which has 100% exposure to AMD&#8217;s peer Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) saw an 11.78% increase, trading at $52.65, up from Tuesday&#8217;s close of $47.10. 
The Direxion Daily Semiconductor Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>) also experienced a significant boost, trading 10.71% higher at $41.23, compared to its previous close at $37.24.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40038854/why-bitcoin-etf-gbtc-is-down-a-whopping-10-today?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Why Bitcoin ETF GBTC Is Down A Whopping 11% Today</a>
ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>) followed suit, with an 8.73% increase, trading at $110.98, a significant rise from Tuesday&#8217;s close at $102.07. The VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) saw a 4.20% increase, trading at $239.10, up from $229.47. Lastly, the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) rose by 3.69%, trading at $228.73, up from $220.58 on Tuesday.
Why It Matters: The Biden administration announced <a href="https://www.benzinga.com/24/07/40061267/asml-shares-surge-over-7-as-team-biden-plans-to-exempt-allies-from-new-rule-on-foreign-chip-equipmen">the new rule </a>on foreign chip equipment exports to China which will enhance U.S. authority to halt exports of semiconductor manufacturing equipment from certain foreign countries to Chinese chipmakers. However, shipments from key allies such as Japan, the Netherlands, and South Korea will be exempted, thereby limiting the rule's impact.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/40029681/trump-accuses-opec-of-manipulating-oil-prices-to-favor-kamala-harris-warns-she-will-be-a-disaste?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Accuses OPEC Of Manipulating Oil Prices To Favor Kamala Harris, Warns &#8216;She Will Be A Disaster For The USA!&#8217;</a></li>
</ul>
Picture by blickpixel on Pixabay and Karolina Grabowska on Pexels and Osman Bugra Nuvasil on Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Sector ETFs

Pre-Market Outlook

ETFs

NVDA

NVDL

SOXL

iShares PHLX SOX Semiconductor Sector Index Fund

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

MiniLuxe Hldg

News

Latest news for MiniLuxe Hldg (OTC:MNLXF) Stock